Eli Lilly and Company will present data from its cardiometabolic portfolio at the 62nd Annual Meeting of the European Association for the Study of Diabetes in Milan from Sept. 28 to Oct. 2, 2026. Phase 3 TRIUMPH-2 results showed investigational retatrutide, a once-weekly GIP, GLP-1 and glucagon triple receptor agonist, produced average weight loss of up to 49.6 pounds, or 20.8%, and reduced A1C by up to 1.6% after 80 weeks in adults with obesity or overweight and type 2 diabetes. Lilly will also present cardiovascular data for Mounjaro and Foundayo, including Mounjaro's non-inferiority to Trulicity and lower observed risks of MACE-3 and MACE-4 events for Foundayo versus insulin glargine. Phase 2 findings for eloraTZP, an investigational combination of eloralintide and tirzepatide, will be presented alongside Phase 1 data showing 17% weight loss over 16 weeks when eloralintide 3 mg was added to tirzepatide 5 mg, compared with 10% for tirzepatide alone. The update follows Lilly's second-quarter 2026 results, which included $22.97 billion in worldwide revenue, a 48% year-over-year increase, non-GAAP EPS of $8.38 and a raised full-year revenue outlook of $85 billion-$87 billion. Shares were up 1.34% at $1,153.50 in premarket trading Tuesday, according to Benzinga Pro data.